Eli Lilly (LLY) believes its experimental weight-loss pill could make GLP-1 treatments more accessible worldwide.
Eli Lilly’s rising fortunes tied to its weight loss and diabetes drugs led to a nine-figure payday for its top executive.
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.
Zepbound contains the same active ingredient, tirzepatide, as Mounjaro, which is also made by Lilly and is FDA-approved to treat Type 2 diabetes. Some doctors also prescribe Mounjaro "off-label" for ...
Consumers who use telehealth or medical spas to get less expensive, compounded weight loss drugs will need to get their ...
How weight loss drugs actually work, and how big-name prescriptions differ from each other. What investors need to know about Ozempic's and Mounjarno's patent cliffs. The scenarios in which Novo ...
MariTide’s opportunity in diabetes should not be ignored. In addition to reducing weight by 17%, it reduced HbA1c up to 2.2% ...